A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentric Trial [Etude d'efficacite et d'acceptabilite d'un traitement cholinergique dans l'apathie parkinsonienne "Cholinergic treatment in Parkinsonian Apathy: ChoPA - I"].
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2014
At a glance
- Drugs Rivastigmine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms CHoPA-I
- 23 Apr 2012 Actual patient number is 40 as reported by ClinicalTrials.gov.
- 23 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Feb 2011 Planned end date changed from 1 Apr 2010 to 1 Jan 2012 as reported by ClinicalTrials.gov.